Financial Performance - In 2024, the company achieved a net profit attributable to shareholders of RMB 242,688,462.41, representing a 21.60% increase compared to RMB 199,585,789.80 in 2023[23] - The company's operating revenue for 2024 was RMB 2,686,037,568.67, a decrease of 7.69% from RMB 2,909,765,256.74 in 2023[23] - The net cash flow from operating activities for 2024 was RMB 471,694,572.82, down 5.20% from RMB 497,553,579.83 in 2023[23] - The total assets at the end of 2024 were RMB 3,543,942,574.34, an 8.04% decrease from RMB 3,853,636,709.00 at the end of 2023[24] - The net assets attributable to shareholders at the end of 2024 were RMB 2,892,638,654.66, a decrease of 2.81% from RMB 2,976,188,510.38 at the end of 2023[24] - The company reported a net profit excluding non-recurring gains and losses of RMB 215,457,408.25 for 2024, which is a 19.60% increase from RMB 180,147,228.32 in 2023[23] - Basic earnings per share increased to 0.3356 yuan, representing a growth of 28.34% compared to the previous year[25] - The weighted average return on equity rose to 8.41%, an increase of 1.75 percentage points from the previous year[25] Dividend Policy - The company plans to distribute a cash dividend of RMB 3 per 10 shares (including tax) based on the total share capital as of the dividend record date[6] - The company has maintained a consistent dividend policy without any plans for stock issuance or capital reserve conversion[6] - The cash dividend payout ratio was 86.53% of the net profit attributable to ordinary shareholders, which was RMB 242.69 million[168] - The cumulative cash dividend over the last three accounting years was RMB 356.5 million, with a cash dividend ratio of 372.22% of the average annual net profit[170] Market and Product Development - The company plans to focus on pediatric products while optimizing resource allocation for high-quality development[33] - The company is navigating a challenging environment with ongoing pressures from national procurement policies and regulatory compliance in the pharmaceutical industry[33] - The company obtained 6 generic drug approvals during the reporting period, including Montelukast sodium granules and sustained-release Nifedipine tablets, and completed 3 generic drug registration applications[36] - The company has made progress in innovative drug development, with projects SY-005 and SY-009 in Phase II clinical trials, and received a clinical approval for SY-009 for functional constipation[37] - The company achieved a market share of 19% for Dinggui Erqi贴 in the prefecture-level city market, an increase of 3 percentage points year-on-year, leading the children's diarrhea treatment market[38] - The company is focusing on pediatric medication, with policies enhancing the development and approval of children's drugs, resulting in 106 new pediatric drug approvals in 2024[42] - The company is actively expanding its adult drug market, achieving successful bids for multiple generic drugs in national procurement[39] Research and Development - The company has 72 domestic invention patents and 40 international invention patents, with 21 pending applications in China and 36 foreign applications[59] - R&D expenses increased by 17.95% to 139.5 million RMB, driven by changes in the timing of capitalizing R&D costs and increased outsourcing[61] - The company has established a production base for transdermal preparations and introduced automated production lines from Germany[58] - The company has launched several key products in the pediatric category, including Dinggui Erqi贴, which is used for treating diarrhea and abdominal pain in children[86] - The company is focusing on expanding its product line in the cardiovascular system, including the development of new chemical drugs[89] - The company is actively researching and developing new products for diabetes-related peripheral neuropathy, including Thioctic Acid Tablets and Injections[89] Environmental Responsibility - The company invested RMB 543.03 million in environmental protection during the reporting period[174] - The company operates a wastewater treatment plant with a daily capacity of 1,000 tons at the Ruicheng Industrial Park, utilizing hydrolysis acidification and anaerobic tower processes, achieving compliance with the GB21905-2008 standard for pharmaceutical wastewater discharge[179] - The company has established environmental emergency response plans for its industrial parks, with the latest revisions filed with local environmental authorities[183] - The company implemented carbon reduction measures, successfully reducing carbon dioxide equivalent emissions by 3,300 tons[186] - The company has installed online monitoring systems for COD and ammonia nitrogen at wastewater discharge points, ensuring real-time compliance with environmental standards[179] Governance and Compliance - The board of directors consists of 9 members, including 4 independent directors, ensuring compliance with governance standards[137] - The company has established a robust investor relations management system to facilitate communication and protect investor rights[138] - The company maintains a commitment to timely and accurate information disclosure, ensuring transparency and fairness for all shareholders[138] - The company strictly implemented the insider information registration system during the reporting period, with no incidents of insider trading reported[140] - The company has a comprehensive governance structure in place, adhering to legal and regulatory requirements without significant discrepancies[141] Workforce and Management - The company reported a total of 3,611 employees, with 2,205 in the parent company and 1,406 in major subsidiaries[160] - The workforce includes 1,699 production personnel, 318 R&D personnel, and 811 sales personnel[160] - The company has established a performance management system to enhance employee productivity and ensure fair performance evaluations[162] - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 20.9062 million yuan[149] - The company has a structured approach to determining the remuneration of its directors and senior management based on performance metrics[149] Strategic Focus - The company aims to enhance its competitive edge through innovation-driven development and optimizing its product pipeline[127] - The company’s future strategy emphasizes internationalization and talent-driven growth, aiming to create a new ecosystem in the pharmaceutical industry[129] - The company recognizes the trend of resource concentration towards leading enterprises in the pharmaceutical sector, driven by innovation and mergers and acquisitions[128] - The company will closely monitor industry policy trends and enhance its response mechanisms to adapt to new regulatory requirements[132]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 614,533,394.31, representing a decrease of 20.32% compared to CNY 771,213,413.14 in the same period last year[3]. - The net profit attributable to shareholders was CNY 107,269,233.54, down 4.45% from CNY 112,264,323.74 year-on-year[3]. - The net cash flow from operating activities decreased by 48.31%, amounting to CNY 144,398,528.45 compared to CNY 279,357,773.45 in the previous year[3]. - The basic earnings per share were CNY 0.1522, a slight decrease of 0.39% from CNY 0.1528 in the same period last year[3]. - Total operating revenue for Q1 2025 was ¥614,533,394.31, a decrease of 20.3% compared to ¥771,213,413.14 in Q1 2024[18]. - Net profit for Q1 2025 was ¥106,068,467.86, a decrease of 3.1% from ¥109,772,004.55 in Q1 2024[19]. - Basic earnings per share for Q1 2025 were ¥0.1522, slightly down from ¥0.1528 in Q1 2024[20]. - The company reported a decrease in sales expenses to ¥111,914,490.55 in Q1 2025 from ¥200,638,292.84 in Q1 2024, a reduction of 44.2%[18]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,569,135,121.87, reflecting a 0.71% increase from CNY 3,543,942,574.34 at the end of the previous year[4]. - The equity attributable to shareholders increased by 1.72%, reaching CNY 2,942,386,032.98 compared to CNY 2,892,638,654.66 at the end of last year[4]. - As of March 31, 2025, the company's total assets amounted to RMB 3,569,135,121.87, an increase from RMB 3,543,942,574.34 as of December 31, 2024, reflecting a growth of approximately 0.71%[12]. - Total liabilities decreased to ¥625,668,979.44 in Q1 2025 from ¥649,023,044.55 in Q1 2024[15]. Cash Flow - The company's cash and cash equivalents increased to RMB 635,590,969.68 from RMB 578,594,453.98, representing a growth of about 9.3%[12]. - Cash inflow from operating activities in Q1 2025 was ¥556,005,952.75, a decrease of 28.4% compared to ¥776,858,863.98 in Q1 2024[23]. - The net cash flow from operating activities was $144,398,528.45, a decrease of 48.3% compared to $279,357,773.45 in the previous period[24]. - Total cash outflow from operating activities amounted to $411,607,424.30, down from $497,501,090.53, reflecting a reduction of 17.2%[24]. - The ending balance of cash and cash equivalents was $635,254,516.80, compared to $659,775,713.49, reflecting a decrease of 3.7%[25]. - The net increase in cash and cash equivalents was $56,996,515.70, down from $94,311,970.88, representing a decline of 39.4%[25]. Shareholder Information - The company had a total of 49,801 common shareholders at the end of the reporting period[7]. - The largest shareholder, Shandong Yabao Investment Group Co., Ltd., held 94,300,000 shares, accounting for 13.47% of total shares, with 31,150,000 shares pledged[8]. - There were no changes in the top 10 shareholders or their shareholding status compared to the previous period[10]. - The company has not identified any related party transactions or agreements among its major shareholders[10]. Operational Insights - The decline in operating revenue was primarily due to decreased sales from specific products, including the anti-inflammatory patch and injection solutions[6]. - The company reported a significant increase in prepayments, which amounted to RMB 67,669,386.30, slightly down from RMB 71,251,512.37[12]. - The company's non-current assets totaled RMB 1,955,255,613.14, down from RMB 1,984,630,806.62, reflecting a decrease of approximately 1.5%[12]. - The company has not disclosed any new product developments or technological advancements during this reporting period[11]. - Research and development expenses for Q1 2025 were ¥21,567,036.65, down 30.4% from ¥31,012,841.20 in Q1 2024[18].

亚宝药业集团股份有限公司董事会 关于独立董事独立性情况的专项意见 亚宝药业集团股份有限公司董事会 2025 年 4 月 24 日 根据证监会《上市公司独立董事管理办法》、上海证券交易所《股票上市规 则》《上市公司自律监管指引第 1 号--规范运作》及《公司章程》《独立董事管 理办法》等要求，亚宝药业集团股份有限公司（以下简称"公司"）董事会就 公司 2024 年在任独立董事余春江、刘俊彦、崔民选、谭勇的独立性情况进行评 估并出具如下专项意见： 经核查公司独立董事余春江、刘俊彦、崔民选、谭勇的任职经历以及其签 署的相关自查文件，上述人员未在公司担任除独立董事以外的其他职务，也未 在公司主要股东公司担任任何职务，与公司及主要股东、实际控制人不存在直 接或间接利害关系或者其他可能影响其进行独立客观判断的关系，不存在影响 其独立性的情形，符合《上市公司独立董事管理办法》《上海证券交易所上市公 司自律监管指引第 1 号--规范运作》中关于独立董事独立性的相关要求。 ...

证券代码：600351 证券简称：亚宝药业 公告编号：2025-012 亚宝药业集团股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：致同会计师事务所（特殊普通合伙） 亚宝药业集团股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 第九届董事会第八次会议，审议通过了《关于续聘会计师事务所的议案》，同意 续聘致同会计师事务所（特殊普通合伙）（以下简称"致同所"）作为公司 2025 年度财务报告及内部控制审计机构，并同意将该议案提交公司 2024 年年度股东 大会审议。 一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 会计师事务所名称：致同会计师事务所（特殊普通合伙） 组织形式：特殊普通合伙企业 成立日期：2011年12月22日 注册地址：北京市朝阳区建国门外大街22号赛特广场五层 首席合伙人：李惠琦 执业证书颁发单位及序号：北京市财政局 NO 0014469 截至 2024 年末，致同所从业人员近 6000 人， ...

亚宝药业集团股份有限公司2024年度非经营性资金占用及其他关 联资金往来情况汇总表 关于亚宝药业集团股份有限公司 非经营性资金占用及其他关联 资金往来的专项说明 致同会计师事务所（特殊普通合伙） 目 录 关于亚宝药业集团股份有限公司非经营性资金占用及其他关联资 金往来的专项说明 Thornton 在北京 特广场5层邮编 10000 关于亚宝药业集团股份有限公司 非经营性资金占用及其他关联资金往来的专项说明 致同专字（2025）第 110A010200 号 亚宝药业集团股份有限公司全体股东: 我们接受亚宝药业集团股份有限公司(以下简称"亚宝药业公司")委 托,根据中国注册会计师执业准则审计了亚宝药业公司 2024 年 12月 31 日的合 并及公司资产负债表,2024年度合并及公司利润表、合并及公司现金流量表、 合并及公司股东权益变动表和财务报表附注,并出具了致同审字(2025)第 110A016978 号无保留意见审计报告。 根据《上市公司监管指引第8号 -- 上市公司资金往来、对外担保的监管 要求》等有关规定,亚宝药业公司编制了本专项说明所附的亚宝药业集团股 份有限公司 2024 年度非经营性资金占用及其他 ...

证券代码：600351 证券简称：亚宝药业 公告编号：2025-014 亚宝药业集团股份有限公司 关于公司变更注册资本、取消监事会并修订公司章程的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、减少注册资本的情况 亚宝药业集团股份有限公司（以下简称"公司"）分别于 2024 年 8 月 14 日、 2024年9月3日召开了第九届董事会第六次会议和2024年第一次临时股东大会， 审议通过了《关于以集中竞价交易方式回购股份方案的议案》，同意公司使用自 有资金以集中竞价方式回购公司股份，回购股份的资金总额不低于人民币 1 亿元 （含）且不超过人民币 1.5 亿元（含），回购股份价格不超过人民币 6.95 元/股， 回购用途为全部予以注销并减少公司注册资本，回购期限为自股东大会审议通过 回购方案之日起不超过 6 个月。 截至 2025 年 3 月 3 日，公司集中竞价交易方式回购股份的回购期限届满， 所回购的股份 20,000,048 股股票已于 2025 年 3 月 4 日在中国证券登记结算有限 责任公司上海分公司办理注销 ...

亚宝药业集团股份有限公司 根据《公司法》《上市公司治理准则》《上海证券交易所上市公司自律监管指 引第 1 号 -- 规范运作》的有关规定及《公司章程》《董事会审计委员会工作细 则》的有关要求,2024年度公司董事会审计委员会本着勤勉尽责的原则,认真履 行相关职责,现将 2024年度履职情况报告如下: | 召开目期 | 会议届次 | 会议内容 | | --- | --- | --- | | 2024 年 1 | 童事会审计委员 会 2024 年第一 | 审议通过《公司 2023年度审计工作安排》 | | 月9日 | 次会议 | | | | 董事会审计委员 | 同意将公司按照《企业会计准则》和《企业会 | | 2024 年 1 | 会 2024 年第二 | 计制度》及有关补充规定编制的 2023 年度资 | | 月 18日 | 次会议 | 产负债表、利润表、现金流量表、股东权益变 | | | | 动表提交致同会计师事务所予以审计。 | | 2024 年 4 | 童事会审计委员 | 对致同会计师事务所出具的初步审计结果中 | | 月 11日 | 会 2024 年第三 | 公司 2023 年度资产负债表、利润表、现金 ...

一、2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 致同会计师事务所(特殊普通合伙)(简称"致同所")前身是成立于1981年 的北京会计师事务所，2011年12月22日经北京市财政局批准转制为特殊普通合 伙，2012年更名为致同会计师事务所(特殊普通合伙)。 亚宝药业集团股份有限公司审计委员会 对会计师事务所 2024 年履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》和亚宝药业股份有限 公司（以下简称"公司"）的《公司章程》《董事会审计委员会工作细则》等规 定和要求，董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现 将董事会审计委员会对会计师事务所 2024 年度履行监督职责的情况汇报如下： 注册地址：北京市朝阳区建国门外大街22号赛特广场五层。 首席合伙人：李惠琦。 截至 2024 年末，致同所从业人员近 6000 人，其中合伙人 239 名，注册会 计师 1,359 名，签署过证券服务业务审计报告的注册会计师超过 400 人。 （二）聘任会计师事务所履行的程序 公司董事会审计委员会 ...

一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制评价结果推测未来内部控制的有效性具有一定的风险。 二. 内部控制评价结论 公司代码：600351 公司简称：亚宝药业 亚宝药业集团股份有限公司 2024年度内部控制评价报告 亚宝药业集团股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制 ...